Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
7mCT-G32, also called SCO-940, is a preclinical four-receptor obesity candidate. The sponsors reported rat and monkey data at TIDES Europe in November 2026 and plan a US IND in February 2027. Here's how to place that news on the drug-development ladder.
9mSLU-PP-332 is a synthetic small molecule that activates estrogen-related receptors linked to exercise biology. Here is what the mouse studies actually show, and what is still unknown in humans.
8m5-Amino-1MQ dosage searches grew more than 1,400 percent. The stack page already ranks. This companion stays on milligram ranges and oral versus subQ handling language.
8mBPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.
9mThe new BPC-157 review is useful because it separates mechanism from marketing. The peptide looks biologically interesting, but the human evidence is still thin.
7mAfter 30+ years of animal research and 212 preclinical studies, BPC-157 has entered its first Phase 2 human trial. Here's what it will test, what it won't prove, and what to track.
Also available at /blog for legacy links.